Enhanced efficacy of selumetinib by pretreatment of 5-FU in preclinical Ras/Raf-mutant colorectal cancer models

被引：0
|
作者：
Jang, Hye Yeon
Lee, Haeng Jung
Nam, Yeo Jin
Kim, Won Dong
Bae, Yong Ju
Jung, Jin Hwang
Lee, Seung Jin
Moon, Dae Hyuk
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1204
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
    M A Bensmaïne
    M Marty
    A de Gramont
    S Brienza
    F Lévi
    M Ducreux
    E François
    E Gamelin
    H Bleiberg
    E Cvitkovic
    British Journal of Cancer, 2001, 85 : 509 - 517
  • [32] Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors
    Hong, Theodore S.
    Wo, Jennifer Yon-Li
    Ryan, David P.
    Zheng, Hui
    Borger, Darrell R.
    Kwak, Eunice Lee
    Allen, Jill N.
    Berger, David L.
    Rattner, David W.
    Cusack, James C.
    Gemma, Angelo J.
    Mamon, Harvey J.
    Eyler, Christine E.
    Shellito, Paul C.
    Zhu, Andrew X.
    Goyalx, Lipika
    Goyal, Lipika
    Clark, Jeffrey W.
    Willers, Henning
    Haigis, Kevin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
    Bensmaïne, MA
    Marty, M
    de Gramont, A
    Brienza, S
    Lévi, F
    Ducreux, M
    François, E
    Gamelin, E
    Bleiberg, H
    Cvitkovic, E
    BRITISH JOURNAL OF CANCER, 2001, 85 (04) : 509 - 517
  • [34] Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models
    Scavo, Maria Principia
    Cutrignelli, Annalisa
    Depalo, Nicoletta
    Fanizza, Elisabetta
    Laquintana, Valentino
    Gasparini, Giampietro
    Giannelli, Gianluigi
    Denora, Nunzio
    PHARMACEUTICS, 2020, 12 (07) : 1 - 19
  • [35] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
    Pietrantonio, Filippo
    Bergamo, Francesca
    Rossini, Daniele
    Ghelardi, Filippo
    De Grandis, Maria Caterina
    Germani, Marco Maria
    Barsotti, Giulia
    Formica, Vincenzo
    Frassineti, Giovanni Luca
    Boscolo, Giorgia
    Cinieri, Saverio
    Di Donato, Samantha
    Antonuzzo, Lorenzo
    Antoniotti, Carlotta
    Ambrosini, Margherita
    Piva, Vittoria Matilde
    Nichetti, Federico
    Fassan, Matteo
    Cremolini, Chiara
    Lonardi, Sara
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [37] Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer -: a pooled analysis of clinical trials.
    Folprecht, G
    Cunningham, D
    Glimeilius, B
    Dicostanzo, F
    Wils, J
    Scheithauer, W
    Rougier, P
    Aranda, E
    Pabst, U
    Köhne, CH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 740S - 740S
  • [38] Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer A meta-analysis
    Chen, Ke
    Gong, Yinya
    Zhang, Qi
    Shen, Yanping
    Zhou, Taoqi
    MEDICINE, 2016, 95 (46)
  • [39] Resistance of colorectal cancer cells to 5-FU treatment in three dimensional cell culture models under perfusion involves BCL-2
    Hirt, Christian
    Papadimitropoulos, Adam
    Panopoulos, Evangelos
    Mele, Valentina
    Muraro, Manuele
    Cremonesi, Eleonora
    Droeser, Raoul
    Mengus, Chantal
    Heberer, Michael
    Oertli, Daniel
    Iezzi, Giandomenica
    Zajac, Paul
    Eppenberger-Castori, Serenella
    Tornillo, Luigi
    Terracciano, Luigi
    Martin, Ivan
    Spagnoli, Giulio
    CANCER RESEARCH, 2014, 74 (19)
  • [40] 5-FU/LV + cetuximab plus vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
    Ducreux, M.
    Tabernero, J.
    Grothey, A.
    Arnold, D.
    O'Dwyer, P.
    Perdicchio, M.
    Assaf, Z.
    Das Thakur, M.
    Irahara, N.
    Tahiri, A.
    Schmoll, H.
    Van Cutsem, E.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S221 - S222
12345